**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 64621

**Manuscript Type:** MINIREVIEWS

**Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects**

Loinaz-Segurola C *et al*. COVID-19 in liver transplantation

Carmelo Loinaz-Segurola, Alberto Marcacuzco-Quinto, Mario Fernández-Ruiz

**Carmelo Loinaz-Segurola, Alberto Marcacuzco-Quinto,** HBP and Transplant Surgery Unit. Department of General Surgery, Digestive Tract and Abdominal Organ Transplantation, Hospital Universitario “12 de Octubre”, Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Universidad Complutense, Madrid 28041, Spain

**Mario Fernández-Ruiz,** Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Universidad Complutense, Madrid 28041, Spain

**Author contributions:** Loinaz-Segurola C and Marcacuzco-Quinto A performed the literature review on the clinical aspects and wrote the related text; Fernández-Ruiz M reviewed mainly the therapeutics issues and wrote the related text; All the authors reviewed the paper and approve the final manuscript.

**Corresponding author: Carmelo Loinaz-Segurola, FACS, MD, PhD, Associate Professor,** HBP and Transplant Surgery Unit. Department of General Surgery, Digestive Tract and Abdominal Organ Transplantation, Hospital Universitario “12 de Octubre”, Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12), Universidad Complutense, Avenida de Cordoba s/n, Madrid 28041, Spain. cloinaz@ucm.es

**Received:** February 21, 2021

**Revised:** June 17, 2021

**Accepted:** August 23, 2021

**Published online:** October 27, 2021

**Abstract**

The coronavirus disease 2019 (COVID-19) pandemic has profoundly impacted liver transplant (LT) activity across the world, with notable decreases in the number of donations and procedures in most Western countries, in particular throughout the first wave. The cumulative incidence of COVID-19 in LT recipients (with estimates ranging from 0.34% to 1.56%) appears to be at least comparable to that observed for the general population. Clinical and radiological features at presentation are also similar to non-transplant patients. The risk of death among LT recipients requiring hospital admission is high (from 12% to 19%), although some authors have suggested that overall mortality may be actually lower compared to the general non-transplant population. It is likely that these poor outcomes may be mainly influenced by the older age and higher comorbidity burden of LT recipients, rather than by the transplant status itself. In fact, it has been hypothesized that post-transplant immunosuppression would exert a protective role, with special focus on tacrolimus-containing regimens. There is scarce evidence to guide the optimal management of post-transplant COVID-19 and the use of antiviral or immunomodulatory therapies, although both clinical practice and guidelines support the dose reduction or withdrawal of anti-proliferative agents such as mofetil mycophenolate. Preliminary reports suggest that the antibody response to messenger RNA vaccines is significantly impaired as compared to non-immunocompromised individuals, in line with other transplant populations. Finally, it is foreseeable that the future will be conditioned by the emerging variants of severe acute respiratory syndrome coronavirus 2 with increased transmissibility among LT recipients.

**Key Words:** COVID-19; Liver transplantation; Clinical features; Therapy; Immunosuppression; SARS-CoV-2

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Loinaz-Segurola C, Marcacuzco-Quinto A, Fernández-Ruiz M. COVID-19 in liver transplant patients: Clinical and therapeutic aspects. *World J Hepatol* 2021; 13(10): 1299-1315

**URL:** https://www.wjgnet.com/1948-5182/full/v13/i10/1299.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v13.i10.1299

**Core Tip:** Coronavirus disease 2019 incidence and clinical and radiological features are similar in liver transplant recipients and the general population. Reported mortality in hospitalized patients is 12%-19%. Risk factors are older age and comorbidity. Tacrolimus could be protective, but anti-proliferative agents such as mycophenolate mofetil should be avoided.

**INTRODUCTION**

The coronavirus disease 2019 (COVID-19) produced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019[1,2]. The initial outbreak rapidly spread all over the world, being declared a pandemic by the World Health Organization by March 11, 2020, with 118000 cases declared in 114 countries and 4291 deaths at that time[3]. The pandemic has now affected more than 172 million people and has reached a death toll exceeding 3.7 million[4,5].

Liver transplant (LT) recipients are considered susceptible to infectious complications due to their long-term immunosuppression (IS)[6]. At the time COVID-19 was first described, the potential impact of this emerging condition on this patient population was unpredictable. Previous experiences with related coronaviruses, such as SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV), did not clearly show an increased incidence or case-fatality rate among immunocompromised patients[7,8]. A systematic review and meta-analysis that summarized the literature available between January and April 2020 identified hypertension, diabetes, cardiovascular disease, chronic obstructive pulmonary disease, malignancy, cerebrovascular disease, and human immunodeficiency virus infection as risk factors for severe COVID-19 in the Chinese population. Of note, chronic liver disease was not identified in this preliminary study[9]. Nevertheless, a systematic review focused on solid organ transplantation (SOT), which pooled 60 studies from January to October 2020 and 2772 unique patients, including 505 LT recipients , revealed high rates of both hospitalization (81.0%) and all-cause mortality (18.6%)[10].

In the present review, we summarize the current experience regarding COVID-19 in LT recipients, with particular focus on clinical and therapeutic aspects. Early experiences from different locations all over the world led to the scientific societies to develop guidelines for the management of these patients. This pandemic has exerted a deep impact on the transplant activity. There remain concerns about the medium- and long-term outcomes of infected recipients as well as on the optimal management of IS.

**Early experiences**

On April 19, 2020 it was reported from Wuhan a 50-year-old male patient that had undergone LT in 2017 and developed SARS-CoV-2 pneumonia with mild respiratory failure by the end of January. Tacrolimus was restarted 4 wk later, with normal liver function. The authors suggested that reduction or temporary withdrawal of IS may be beneficial for the reconstitution of the immune response[11]. Huang *et al*[12] subsequently reported a second 59-year-old LT recipient that died on 45 d of admission due to multiorgan failure in the setting of suspected chronic rejection and septic shock.

During March 2020, three long-term (> 10 years) LT recipients that were receiving low-dose IS and rapidly developed acute respiratory distress syndrome (ARDS) requiring mechanical ventilation died at the Istituto Nazionale Tumori in Milano between 3 and 12 d after the onset of symptoms. Three other recipients that developed COVID-19 less than 2 years from transplantation had an uneventful disease. This led the authors to suggest that post-transplant IS might be protective, whereas metabolic-related comorbidities would be associated with an increased risk of severe infection[13].

Six LT recipients from our institution had been admitted by March 23, 2020. Two of them died due to ARDS associated to renal failure and refractory shock, respectively. Both patients were receiving mycophenolate mofetil (MMF) at admission, associated to everolimus in the first case. Two further LT recipients were treated as outpatients. Two patients were temporarily converted to tacrolimus, MMF was halted in one patient, and no modifications were made in the remaining three[14].

 Some of the earliest cases of post-transplant COVID-19 from the United States were reported on March 22, 2020. These 4 cases included a 67-year-old man that had undergone LT 19 years before. The patient was initially admitted to the intensive care unit (ICU), cyclosporine therapy was continued without adjustment, and he was discharged home after 6 d[15]. A report from New York City described the initial experience at two centers during the first weeks of the outbreak, including 13 LT recipients, four of them with severe disease. Sixteen out of 90 SOT recipients died, resulting in an overall case-fatality rate of 18%, 24% for hospitalized patients and 52% for those admitted to the ICU[16].

Shortly after the outbreak of the pandemic, first experiences with recent transplant recipients started to be reported. For instance, a 69-year-old patient admitted for LT on January 28, 2020 in Iran became febrile on post-transplant day 4, being diagnosed with hospital-acquired pneumonia. He developed respiratory failure and loss of consciousness on day 9. A brain computerized tomography (CT) scan revealed a hypodensity in the right parietal lobe suggestive of middle cerebral artery ischemic stroke. The patient died on day 23 after transplantation, with SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) being reported positive on the next day[17]. Qin *et al*[18] reported a 37-year-old male patient that underwent LT on January 21, 2020. He started with persistent fever on post-transplant day 9, and a thoracic CT scan revealed minor changes. A second scan performed 9 d later showed multiple ground glass opacification in the left lobes. Tacrolimus and steroids were maintained though titrated to lower doses, and supplemental oxygen therapy through high-flow nasal cannula maintained oxygen saturation ranging from 95% to 99%. The patient was successfully discharged 51 d after transplantation[18].

**COVID-19 and the liver**

Although COVID-19 is primarily a respiratory disease, SARS-CoV-2 may also infect the digestive system through its viral receptor angiotensin-converting enzyme 2 (ACE2). The ACE2 cell surface receptor is more strongly expressed in cholangiocytes, at a similar level in fact than type 2 alveolar cells in the lungs, than hepatocytes (59.7% *vs* 2.6%, respectively)[19]. Increased transaminases is a common laboratory finding in COVID-19, and liver injury has been associated to drug-induced liver toxicity, systemic hyperinflammatory response, or hypoxia-ischemia reperfusion injury[20], rather than direct viral cytopathic effect[21]. Coagulopathy and liver endotheliopathy have been suggested to be at least partially driven by interleukin (IL)-6 trans-signaling, which would lead to the expression of procoagulant (such as factor VIII or von Willebrand factor) and proinflammatory factors as well as increased platelet attachment in liver sinusoidal endothelial cells. Interestingly, these effects were blocked by soluble gp130, which acts as an IL-6 trans-signaling inhibitor, and the janus kinase inhibitor ruxolitinib, providing support for these therapeutic approaches[22]. Histopathologic features suggestive of some level of cytopathic injury, however, have been also observed in liver biopsies[23].

Cai *et al*[24] reported in a large cohort that individuals with abnormal liver tests were at a higher risk of progression to severe COVID-19. Abnormal liver function was observed in 76.3% of patients, with 21.5% of them developing liver injury. The detrimental effect on liver function was mainly related to therapies used during hospitalization, which should be closely monitored and evaluated.

In a retrospective study from Wuhan, 1282 out of 2073 patients (61.8%) had abnormal liver function test during hospitalization, and 14.3% experienced some degree of liver injury. Increased aspartate aminotransferase (AST) and direct bilirubin levels at admission were independent predictors of all-cause mortality, whereas the presence of hepatitis B virus infection did not increase the risk of poor outcome[25].

In a retrospective cohort comprising 234 patients hospitalized in two referral hospitals in France, the rate of abnormal liver function tests at admission was as high as 66.6% and was associated with in-hospital aggravation [odds ratio (OR): 4.1: 95% confidence interval (CI): 1.5-10.8; *P* = 0.004] and mortality (OR: 3.3; 95%CI: 1.04–10.5; *P* = 0.04). A minority of patients (3.8%) had underlying liver disease, and there were no significant differences in the prevalence of alcohol consumption or metabolic syndrome between patients with or without abnormal liver tests on admission, suggesting that this finding may be COVID-19-related and not due to pre-existing liver disease[26].

In a retrospective cohort from New York that included 2273 patients, acute liver injury was common and categorized as mild [alanine transaminase (ALT) levels < 2 times the upper limit of normal (ULN)] in 45% of the cases, moderate (ALT levels two to five times the ULN) in 21%, and severe (ALT levels > 5 times the ULN) in 6.4%. In the multivariate analysis adjusted for age, body mass index, comorbidities, and requirement of invasive mechanical ventilation (IMV) and renal replacement therapy, peak ALT levels were significantly associated with death or discharge to hospice (OR: 1.14; *P* = 0.044)[27].

Underlying cirrhosis has been identified as a risk factor for increased severity of COVID-19, with mortality rates ranging from 12% to 43%[28]. Indeed, SARS-CoV-2 may produce acute-on-chronic liver failure (ACLF) among cirrhotic patients[29]. The mortality in 20 patients with ACLF reported from India reached 30%, as compared to 5% among cirrhotic patients without ACLF[30]. Metabolic dysfunction-associated fatty liver disease has been also associated with the severity of SARS-CoV-2 infection in patients below 60 years (OR: 4.07; 95%CI: 1.20–13.79; *P* = 0.02)[31].

In the earlier post-mortem examinations, Xu *et al*[32] found moderate microvesicular steatosis and mild inflammatory infiltrates in the hepatic lobule and portal tract. Mild sinusoidal dilatation, focal macrovesicular steatosis, and mild lobular lymphocytic infiltration has been also reported[33]. Fiel *et al*[23] described the biopsies of two patients that successfully recovered from COVID-19, showing a mixed inflammatory infiltrate with prominent bile duct damage, endothelitis, and numerous apoptotic bodies. *In situ* hybridization and electron microscopy suggested the intrahepatic presence of SARS-CoV-2, thus supporting the possibility of a direct cell injury.

Macrovesicular steatosis was the most common finding (75%) in 40 liver biopsies from patients that died due to a complicated COVID-19 course. Mild lobular necroinflammation and portal inflammation were present in 20 cases each (50%), whereas viral RNA was detected by RT-PCR on liver tissue in 55% of patients tested[34].

 Both the diagnosis and treatment of cancer have been negatively affected by the COVID-19 pandemic and the resulting pressure on the health care services worldwide. Patients with hepatocellular carcinoma (HCC) represent a vulnerable population with a significant treatment delay. In a multicenter, retrospective study performed in Paris, Amaddeo *et al*[35] found a significant decrease in the number of patients with HCC presented to the multidisciplinary tumor committee. The proportion of patients that experienced a treatment delay longer than 1 mo increased between 2019 and 2020 from 9.5% to 21.5%.

**Impact of COVID-19 on LT activity**

The effect of the pandemic has been heterogeneous in terms of donation and transplant activity. Nevertheless, a notable reduction has been reported from most institutions across Europe and North America during the peak of COVID-19 incidence, mainly related to the burden of patients admitted to the ICU and the associated effects on candidate referral and perioperative care[36]. Such a decrease in LT activity was particularly profound in March and April 2020, during the first wave that affected many Western countries. De Simone described the reorganization of LT units carried out in so many centers worldwide during the first wave: Cancellation of routine patient follow-up, outpatient care limited to recent LT recipients, pre-transplant referral limited to priority patients after telephone triage, follow-up by means of phone calls on the waiting list, and implementation of health care worker (HCW) safety policies[36]. This rapid reorganization allowed for maintaining the activity of a high-volume center in Pisa during the Italian national lockdown (February 18 to May 4, 2020), despite the marked drop observed between March 16 and April 5. This was achieved due to the increase in ICU bed capacity, systematic screening for SARS-CoV-2, creation of COVID-19-dedicated ICUs, recruitment of additional medical and nurse staff, rescheduling of elective surgery to priority cases, and continuation of LT activities in COVID-19-free areas[37].

A preliminary analysis of the impact on Italian LT programs was done by means of a survey issued on March 16, 2020 and completed by 22 centers[38]. There were two major geographical areas with different incidence of SARS-CoV-2 infection, north-central Italy and south-central Italy. Between February 15 and March 15, all transplant programs reduced their outpatient activity by 68% in terms of pre-transplant evaluation and 100% in the post-transplant face-to-face follow-up. A reduction in transplant activity was also seen in northern-central Italy during the first 2 wk of March, but not in the southern-central area. Recovered donors dropped by 46% during the first peak (the 4-wk period after February 23) as compared to the preceding 8-wk period[39].

In Spain, according to data provided by the Spanish National Transplant Organization [Organización Nacional de Trasplantes (ONT)], the mean number of donors declined since the national state of alarm was declared on March 13 from 7.2 to 1.2 per day, and the mean number of transplants from 16.1 to 2.1 per day[40]. There was a saturation of the health care system and ICU capacities (although most hospitals had increased the number of ICU beds), and many HCWs became infected (15.5% of the infected population at that time) or forced to quarantine. The number of potential donors declined due to the decrease in neurocritical patients or due to a positive result in SARS-CoV-2 screening. In addition, logistical problems arose as a consequence of the restricted mobility and declining organ offers following a risk assessment that included the clinical situation of the recipients, and even human resources were reduced due to cases of COVID-19 among HCWs. Finally, in the pandemic scenario, some candidates refused transplantation after informed consent[40].

The impact of the first wave on the LT activity in France resulted in an overall 28% decrease in the number of donations when comparing the first 4 mo of 2019 with the corresponding period of 2020, whereas the number of LT effectively performed dropped by 22%. The north-eastern region of the country (with the highest incidence rate of COVID-19) experienced reductions in multiorgan procurement and LT activity of 33% and 26%, respectively[41].

A national state of emergency was declared in the United States by March 13, 2020. A retrospective analysis of data collected from January 5 to September 5, 2020 by the Organ Procurement and Transplantation Network revealed a decrease of 37% in the number of LT procedures performed between March 8 and April 5[42]. Since mid-March, many waitlist patients were placed in temporarily inactive status due to COVID-19 concerns. This practice affected over 2000 waitlist registrations during the week of March 22. LiveOnNY, the organ procurement organization for the greater New York metropolitan area, suffered a drop to 10 donors in April 2020 from 26 in March, although this figure recovered to 18 donors in May[43].

A multinational study performed in India, the United Kingdom, and the United States compared the weekly organ donation and LT numbers over a 3-mo period (February 17 to May 17, 2020) and the LT activity in six centers with varying local COVID-19 caseload[44]. Peak reduction ranged from 25% in the United States to more than 80% in the United Kingdom and India.

On the contrary, the impact of COVID-19 on LT activity has been reported to be almost negligible in other countries. Lee concluded that establishing safe processes and procedures can be beneficial in reducing the negative effects of the national lockdown and saving patients’ lives, as he analyzed LT procedures performed in South Korea[45]. He compared the MERS outbreak, the COVID-19 pandemic, and the average number of LT performed throughout the prior 5 years. There was a significant decrease of 11% in the LT activity during the MERS outbreak, although the number of procedures was maintained from January to March 2020. In addition, none of the 401 patients undergoing LT during the COVID-19 outbreak were confirmed to be infected with SARS-CoV-2. Some Italian centers located in medium- or high-incidence areas were also able to maintain a stable LT activity by means of appropriate screening and isolation practices, dedicated COVID-19-free routes, and reorganization of ICU resources[36,46,47].

 A great variability in the adaptation of LT practices in response to the COVID-19 pandemic has been observed within the same country and even the same region[48]. On the other hand, the detrimental impact on LT activity seems to have been not restricted to those areas facing the highest COVID-19 burden. According to Agopian *et al*[48] such differences across centers likely reflect variations in the allocation and prioritization of hospital resources, local capacities to timely screen for SARS-CoV-2 infection among SOT candidates and recipients, and concerns with respect to donors (*e.g.,* accuracy of testing), recipients (*e.g.,* role of baseline IS), and transplant team members (*e.g.,* risk of hospital-acquired COVID-19).

The effect on the LT waiting list in the United States has been studied by Strauss *et al*[49] using data from the Scientific Registry of Transplant Recipients. From March 15 to April 30, new listings were 11% lower than expected, and deceased donor LTs (DDLTs) decreased by 9%. In May, new listings were 21% lower and living donor LTs were 42% lower, whereas DDLTs increased by 13%. In states with the highest incidence of COVID-19, the number of deaths in the waiting list increased by 59%. By August, waitlist outcomes were occurring at expected rates except for DDLT. According to the authors, these results reflect the adaptability of the transplant community in addressing the COVID-19 pandemic and applying new knowledge to patient care.

 Putzer *et al*[50] found a 29% decrease in the number of LT procedures performed in the Eurotransplant area between mid-March and mid-June 2020, with regards to the corresponding periods from 2015 to 2019. Of note, the activity in Germany continued at the same pace during the initial phase of the crisis, likely thanks to the higher number of ICU beds in that country. However, the number of LTs increased slowly compared to the first month of observation.

**Incidence of COVID-19 in LT recipients**

According to the survey performed by the European Liver and Intestine Transplantation Association (ELITA) and the European Liver Transplant Registry (ELTR), the crude incidence of SARS-CoV-2 infection among LT candidates and recipients during the first wave in Europe has been overall estimated in 1.05% (range: 0.5%-20%) and 0.34% (range: 0.1%-4.8%), respectively[51]. One hundred nine out of 149 (73.2%) ELTR centers located in 28 European countries responded to the survey. Eighty-eight centers reported the diagnosis of COVID-19 in 57 LT candidates and 272 recipients. The highest numbers of infected recipients were reported from Spain (77), Italy (66), and France (59). Crude case fatality rates in candidates and recipients were 18% and 15%, respectively. The authors concluded that both LT candidates and recipients are at high risk of COVID-19 and highlighted the need for an early and proactive screening for SARS-CoV-2 infection in these populations.

Cumulative incidence of COVID-19 has been highly variable across European countries. The King´s College group only reported 5 cases out of about 4500 LT recipients (0.1%) followed-up in their institutional cohort during the first wave[52]. In fact, LT recipients appeared to have a lower incidence of COVID-19, with less severe symptoms, as compared to the general population or other SOT populations, likely due to the better individual adherence to self-isolation recommendations or the optimal level of IS, which would favorably modulate the response against SARS-CoV-2.

A nationwide study promoted by the Spanish Liver Transplantation Society (SETH) recruited 111 LT patients from February 28 to April, 7 2020 and revealed a higher incidence of COVID-19 compared to the general population, almost doubling the expected number of cases[53]. A preliminary experience from our institution showed a cumulative incidence from March 15 to May 5 of 1.6% (19 out of 1200) among LT recipients compared to 0.95% in the general population of Madrid, although potential underreporting due to limited diagnostic capacities at that time could not be ruled out[54].

A detailed study carried out in the United Kingdom comprised SOT recipients diagnosed with SARS-CoV-2 infection in England up to May 20, 2020 and showed a cumulative incidence of 1.3% and 0.7% (64 out of 8734) for the specific group of LT recipients[55].

As the pandemic evolved during 2020, different institutions and groups have provided updated epidemiological data. On the basis of data collected by the Italian Information Transplant System until June 22, Trapani *et al*[56] found a cumulative incidence of 1.02% among SOT recipients as compared to 0.4% in the non-transplant population (*P* < 0.05). This figure was lower (0.63%) for LT recipients. Authors from the Shiraz University of Medical Sciences in Iran, one of the largest transplant centers in the world, published their results by mid-July[57]. They found 85 cases of COVID-19 among abdominal transplant recipients (66 in LT recipients). As of July 2020, 0.32% of the population of the country was infected, with a mortality rate of 5.1%. Among 6969 SOT recipients followed-up at their center, 85 (1.21%) had been diagnosed with COVID-19, and 17 (20%) had died. Their conclusion was that LT and kidney transplant recipients face a poorer outcome due to COVID-19.

Not surprisingly, cumulative incidence has steadily increased over the last months, reflecting variations in the epidemiology of COVID-19 in the general population. In our institution, we have registered 67 cases of SARS-CoV-2 infection by the end of January 2021, accounting for more than 5% of followed-up LT recipients (data not published).

**Risk factors for severe COVID-19 in LT recipients**

In an early retrospective, multicenter cohort study, Zhou *et al*[58] reported detailed clinical course and risk factors for mortality in 191 non-transplant patients with COVID-19 from Wuhan that had been discharged or died by January 31, 2020. Hypertension (30%), diabetes (19%) and coronary heart disease (8%) were the most common comorbidities in the general population. The authors found that older age, higher Sequential Organ Failure Assessment score and D-dimer levels above 1 μg/mL on admission were associated with in-hospital death at multivariable regression.

Mainly reflecting the risk factors identified in the general population, older age, the presence of chronic comorbidities (congestive heart failure, chronic obstructive pulmonary disease, or obesity), lymphopenia (absolute lymphocyte count < 0.5 x 109 cells/L), and abnormal chest imaging at admission were independently associated with mortality (20.5%) in a cohort study comprising 482 SOT recipients (73 LT recipients) from more than 50 United States centers[59].

Preliminary data from the ELITA/ELTR registry on 103 LT recipients diagnosed with COVID-19 between March 1 and April 24, 2020 revealed the following co-morbidities: Overweight (56%), hypertension (51%), diabetes (41%), chronic renal impairment (serum creatinine level > 2 mg/dL) (15%), smoking history (13%), and coronary artery disease (7%). After a median follow-up of 18 d, overall all-cause mortality rate was 16%, but it reached 22% among patients ≥ 60 years and 44% in those requiring IMV[60]. Although the difference did not achieve statistical significance, mortality was found to be lower among patients that had undergone LT within the previous 2 years as compared to those with longer intervals since transplantation (5% *vs* 18%). Of note, all deaths occurred among patients aged 60 years or older.

In the SETH study the most common comorbidity was hypertension (57.7%), whereas risk factors for severe COVID-19 among hospitalized patients included Charlson comorbidity index, male gender, dyspnea at diagnosis, and baseline immunosuppression containing MMF, particularly at doses higher than 1000 mg/d[53].

 The assessment of SARS-CoV-2-attributable mortality after LT must take into account the impact of baseline conditions. A multicenter study from the COVID-Hep and SECURE-Cirrhosis international registries performed between March 25 and June 26, 2020 compared the outcomes of 151 adult LT recipients and 627 patients with SARS-CoV-2 infection who had not undergone transplantation. Older age, serum creatinine levels, and non-liver cancer were associated with mortality. In a propensity score-matched analysis (adjusted for age, sex, major comorbidities, and ethnicity), LT did not significantly increase the risk of death in patients (absolute risk difference: 14%; 95%CI: -7.7–10.4)[61]. Similar findings have been also reported for kidney transplant recipients[62].

**COVID-19 presentation in the setting of LT**

There is a male predominance across different series of LT recipients with COVID-19, from 68%[61] to 78.8%[57]. Median age in adult patients ranges from 60[59] to 65 years[53,60]. Low-grade fever was the most frequent symptom in the earlier reports from Wuhan, followed by cough, fatigue, myalgia, and digestive symptoms (diarrhea, nausea, or vomiting)[58]. Among LT recipients with COVID-19, the presence of fever is also reported in 62.7%[57] to 79%[62] of cases. Cough (with rates ranging from 40.9%[57] to 70.3%[52]), myalgia (37%[60] to 45.5%[57]), fatigue (40.9%[57] to 56%[62]), dyspnea (30.3%[57] to 46%[63]), gastrointestinal symptoms (22.6%[60] to 39.4%[57]), and smell and taste disorders (7%[63]) are also common at presentation.

Becchetti *et al*[63] observed a higher prevalence of fever and dyspnea in long-term LT recipients (more than 10 years from the procedure), whereas the presence of fever and cough was significantly less likely among very short-term recipients (≤ 1 year)[63]. Asymptomatic patients are scarce. In the SETH series they accounted for 6.3% of cases only, whereas most of the patients admitted to the hospital (66%) required some type of respiratory support[52].

Chest X-ray or computed tomography scan showed typical features of COVID-19 in 62% of patients in the series by Belli *et al*[60] and 78.4% in the SETH cohort (unilateral in 19.8% and bilateral in 58.6%)[52]. Becchetti *et al*[63] reported typical radiological features (bilateral, peripheral, consolidation, or ground glass opacities) in 43% of computed tomography scans and 40% of X-ray examinations performed[63].

Only 8% of the patients reported by Becchetti *et al*[63] had a significant increase in transaminases (AST and/or ALT > 2 times the ULN), whereas this figure reached 14.7% in the series by Colmenero *et al*[53]. Mean lymphocyte and platelet counts were decreased in patients with severe disease. Lymphopenia was present in 68.8% of the patients reported by Malekhosseini *et al*[57] and 76% of those reported by Becchetti *et al*[63]. The nadir of absolute lymphocyte count during hospital stay was 0.31 x 109 cells/L among severe cases (versus 0.5 × 109 cells/L in the non-severe forms of infection; *P* = 0.013). Other markers as D-dimers of ferritin levels were significantly higher in severe cases[53], although data were not available for most patients[63].

**Outcome in LT recipients with COVID-19**

The percentage of mild cases managed as outpatients varied in different series from 13.5%[53] to 42.4%[57]. Most of the published cohorts reported rates of hospitalization in the range of 66% to 82%[60,61,63], with a mean hospital stay of 9-10 d[57,63]. Notable variation was observed in the proportion of ICU admission (from 10%[63] to 31.6%[57] of hospitalized patients), which likely reflect regional differences in the availability of critical care resources. Regarding respiratory support, invasive or non-invasive mechanical ventilation was used in 10%[63] to 20%[61] of recipients, including extracorporeal membrane oxygenation in 10.6% of the patients in one series[57].

Reported mortality rates ranged between 12%[61] and 19%[61], close to those observed in large series in the general population (15-21%)[1,64]. Colmenero *et al*[53] showed that, after adjusting for age and gender, the number of observed deaths among LT patients was slightly lower than expected in the general population, resulting in a standardized mortality ratio of 95.55 (95%CI: 94.25–96.85).

Four out of 5 patients that contracted COVID-19 within the first month after transplantation in Shiraz died[57]. The authors attributed this dismal outcome to the higher amount of IS given during the very early post-transplant period. On the other hand, there are several reports on successful recovery in patients diagnosed with SARS-CoV-2 infection very shortly after LT[65-69].

Bhoori *et al*[13] were the first to suggest that long-term LT survivors on minimal IS therapy would face a greater risk of death following COVID-19 infection, thus proposing that a higher IS level could play a protective role. A systematic review pooling outcomes of 223 LT recipients from case-series and cohorts published up to June 15, 2020, however, revealed no significant differences in mortality rates between recent (< 2 years) and remote (≥ 2 years) LT recipients (16.7% *vs* 21.9%, respectively; *P* = 0.5)[70].

**Therapeutic approaches in LT recipients with COVID-19**

***Antiviral therapies***

Most LT recipients included in the series reported during the first pandemic wave were treated with repurposed drugs with *in vitro* activity against SARS-CoV-2, despite the lack of supporting clinical evidence at that time. For instance, the use of hydroxychloroquine (HCQ) (66%), azythromycin (33%), and lopinavir/ritonavir (LPV/r) (17%) was common among LT recipients recruited in the ELITA/ELTR registry between March 1 and April 24, 2020[60]. These rates were even higher in the SETH registry, with as many as 88% and 40% of patients receiving HCQ and LPV/r, respectively[53]. Of note, no differences in the use of these agents were observed according to the severity of COVID-19. In addition, the multicenter registry collected by the ONT in Spain showed that the proportion of recipients treated with protease inhibitors (mainly LPV/r), HCQ, and azithromycin was similar across different SOT populations, suggesting that the therapeutic approach in LT recipients did not substantially differ from that used in patients usually exposed to a higher level of IS, such as heart or lung transplant recipients[71]. As expected, the management of drug-to-drug interactions between LPV/r, a potent cytochrome P450 3A4 inhibitor, and calcineurin or mammalian target of rapamycin (mTOR) inhibitors was particularly challenging[16,72]. In our experience, two LT recipients under everolimus were converted to low-dose prolonged-release tacrolimus (0.5 mg/wk) in order to facilitate the adjustment of IS during hospitalization[54].

No outcome benefit has been demonstrated from the use of LPV/r, HCQ, or subcutaneous interferon-β in the setting of randomized controlled trials (RCTs) conducted over the past months[73-75]. The RNA-dependent RNA polymerase inhibitor remdesivir is the only antiviral agent currently approved for the treatment of COVID-19, in view of the shorter time to clinical recovery obtained with this agent as compared to placebo[76]. The clinical experience with remdesivir in LT recipients, nevertheless, is scarce, with only a few treated patients in large multicenter cohorts[53,71]. Since remdesivir and its main active metabolite GS-441524 are mainly excreted by the kidney, no major drug-to-drug interactions with tacrolimus, MMF, or mTOR inhibitors are to be expected, whereas limited experience with cirrhotic patients has revealed no new safety signals[28]. Abnormal liver function test was not reported as a common adverse event in the ACTT-1 trial, although exclusion criteria included the presence of ALT or AST levels > 5 times the ULN[76].

***Immunomodulatory therapies***

The clinical course of severe forms of COVID-19 is characterized by the presence of an excessive inflammatory response triggered by SARS-CoV-2 and orchestrated by the host immune system, which contributes to the development of tissue damage, multiorgan failure, and ARDS[77]. Such a pathogenic mechanism has led to the widespread use of various immunomodulatory strategies aimed at blocking this “cytokine storm”, including corticosteroids[78], anti-IL-6 (such as tocilizumab or sarilumab)[79] and anti-IL-1β (canakinumab or anakinra)[80] agents, or janus kinase inhibitors (baricitinib)[81]. With the exception of low-to-intermediate-dose systemic corticosteroids (*i.e.* dexamethasone 6 mg daily for 10 d), which have been shown to decrease 28-d mortality in patients requiring respiratory support[82], there remains controversy regarding the clinical benefit to be expected from these agents in the general population with COVID-19, with conflicting results from observational studies and RCTs.

The available evidence supporting the use of immunomodulatory therapies in SOT recipients is even more limited[83]. Nevertheless, multicenter registries revealed that anti-IL-6 agents were commonly administered during the first pandemic wave (with overall rates ranging from 13%[59] to 21%[71]). In the specific group of LT recipients, 5% and 1% of patients included in the ONT registry as of July 2020 had received tocilizumab and anakinra, respectively[71]. The off label use of tocilizumab in other cohorts ranged from 6.2% in the ELITA/ELTR registry[84] to 15.6% in the SETH registry[53]. As previously stated, no RCTs have assessed to date the role of therapeutic IL-6 blockade in the setting of post-transplant COVID-19 with cytokine release syndrome. A small retrospective study compared 29 SOT recipients treated with tocilizumab for severe COVID-19 (including one single LT recipient) with a matched control group of recipients who did not receive this agent. No significant differences were observed in terms of in-hospital mortality (41% *vs* 28%, respectively; *P* = 0.27), hospital discharge (52% *vs* 72%; *P* = 0.26), or secondary infections (34% *vs* 24%; *P* = 0.55), although the higher rates of IMV and renal replacement therapy observed in the tocilizumab group suggest some degree of confounding by indication not completely controlled by the matching process[85].

***Management of immunosuppression***

As commented above, some preliminary reports showing a worse outcome among long-term LT recipients on minimal immunosuppressive regimen (as compared to recently transplanted, fully immunosuppressed patients)[15] led to propose during the first weeks of the pandemic that post-transplant IS might be actually protective in severe COVID-19[86]. Clinical experience accumulated over the past months, however, does not seem to confirm this hypothesis. Indeed, the SETH registry demonstrated the deleterious impact of baseline MMF-containing regimens (particularly when given at doses higher than 1000 mg/d). This negative effect was not observed for calcineurin or mTOR inhibitors. Complete MMF withdrawal during hospitalization showed a trend towards a reduced risk of progression to severe COVID-19 (41.7% *vs* 69.2%; *P* = 0.16)[53].

 The most common adjustment of baseline IS among more than 600 SOT recipients enrolled within the ONT registry was the withdrawal of the anti-metabolite drug (MMF or azathioprine), whereas calcineurin inhibitors were generally managed with dose reduction[71]. It is likely that the impact of baseline IS on the outcome of SARS-CoV-2 infection differ according to individual drugs. Belli *et al*[84] have recently shown that the use of tacrolimus was independently associated with a reduced mortality risk in the ELITA/ELTR registry (hazard ratio: 0.55; 95%CI: 0.31–0.99). The authors propose that tacrolimus could exert a direct antiviral effect through the immunophilin FK506-binding proteins[87].

In accordance with the survival benefit demonstrated for dexamethasone in the RECOVERY trial[82], baseline corticosteroid dose was usually maintained or increased in most LT recipients hospitalized due to COVID-19. In addition, corticosteroids boluses were given in 12.5% of patients in the SETH registry (4.9% and 25.7% of those with non-severe or severe COVID-19, respectively)[53].

**SARS-CoV-2 vaccination in LT recipients**

Whereas messenger RNA SARS-CoV-2 vaccines provide excellent rates of seroconversion and clinical effectiveness in the general population[88,89], immunogenicity in the setting of SOT appears to be severely compromised. Most available reports, however, are focused on kidney[90-92] or lung transplant recipients[93]. In addition, only a few studies have assessed the development of SARS-CoV-2-specific T-cell-mediated immunity in addition to antibody responses[94,95]. Rabinowich *et al*[96] tested for SARS-CoV-2 immunoglobulin G antibodies against the SARS-CoV-2 spike glycoprotein 10-20 d after the administration of the second BNT162b2 vaccine dose in 80 LT recipients. Detectable humoral response was demonstrated in 47.5% of patients only (as compared to 100% of HCWs used as control group). In addition, the mean antibody titer was significantly lower in LT recipients (95.41 AU/mL *vs* 200.5 AU/mL, respectively). Older age, lower estimated glomerular filtration rate, and treatment with MMF or high dose steroids were associated with the lack of vaccine response, with no apparent impact of the time since transplantation. The vaccine was well tolerated, and there were no episodes of suspected or confirmed graft rejection during the follow-up[96]. This disappointing immunogenicity is, however, in line with the rates reported for other SOT populations. The deleterious effect of the anti-metabolite drug has been also shown for kidney and lung transplant recipients[90,93].

**Guidelines for the management of LT during the COVID-19 pandemic**

On November 9, 2020, the American Association for the Study of Liver Diseases (AASLD) issued updated guidelines for LT providers in the current pandemic scenario[97]. Regarding the management of the waiting list, the document recommends to continue to prioritize the initial evaluation of patients with HCC or those with severe disease and high Model for End-stage Liver Disease (MELD) scores who are more likely to benefit from immediate LT listing. Some listed patients should be still seen in person according on the local incidence of SARS-CoV-2 infection and individual patient factors (such as their Model for End-stage Liver Disease score). Telemedicine alternatives may be considered for the remaining candidates. In addition, the AASLD guidelines recommend to develop hospital-specific policies for organ acceptance, taking into account the availability of ICU beds and other hospital resources. Potential donors and recipients must be screened for SARS-CoV-2 exposure and clinical symptoms compatible with COVID-19 (regardless of test results or availability). In addition, all donors and recipients should be screened for SARS-CoV-2, by means of nasopharyngeal swab, bronchoalveolar lavage, or both, taking into account the risk of false negative results, disease prevalence, and testing turnaround time in your area. Alternatives to RT-PCR-based testing such as chest X-ray may also be also considered. Ideally, LT in SARS-CoV-2-positive candidates should be delayed for at least 14-21 d after symptom resolution and one or two negative SARS-CoV-2 diagnostic tests. Of note, the decision to ultimately proceed with LT in a candidate recovering from COVID-19 must be individualized based on several factors (such as the urgency of transplantation, the presence of respiratory symptoms, and the risk of exposing HCWs to SARS-CoV-2).

Regarding the approach to LT recipients diagnosed with COVID-19 in the AASLD guidelines, it should be considered lowering the overall level of IS (particularly anti-metabolite doses) based on general principles for managing post-transplant infections and in order to decrease the risk of secondary infection. The risk of COVID-19-associated kidney injury should be also taken into account and calcineurin inhibitor levels must be closely monitored. Likely due to the lack of supporting evidence, no clear recommendations are provided regarding the optimal regimen and timing for antiviral and immunomodulatory therapies.

In addition, the AASLD expert panel advises against making anticipatory adjustments in current immunosuppressive regimens in LT recipients with no diagnosis of SARS-CoV-2 infection. Prevention measures (*e.g.,* hand washing, cleaning frequently touched surfaces, staying away from large crowds, *etc*.) should be emphasized in this at-risk population[97].

Finally, although specific guidelines on the optimal vaccination strategy are scarce and based on low-level evidence, the Italian Association for the Study of the Liver recommends that LT candidates should be prioritized due to the high risk of mortality in the waiting list. Vaccination of the partners and caregivers of cirrhotic patients and LT recipients should be also encouraged[98].

**CONCLUSION**

Although with geographical differences across countries, COVID-19 has exerted a negative impact on LT transplant activity (both in the number of donors and procedures) during the first months of the pandemic, with decreases ranging from 28% to 46%[38,40,42,43]. The cumulative incidence of SARS-CoV-2 infection in LT recipients has been estimated between 0.34%[50] to 1.56%[52]. These figures appear to be comparable to that observed for the general population, although some studies suggest that the incidence of COVID-19 after LT would be lower as compared to other types of SOT[54]. The clinical and radiological characteristics of COVID-19 at presentation are overall similar to non-transplant patients, including predictive factors of poor outcomes. All-cause mortality among hospitalized recipients is high (from 12%[61] to 19%[59]), and great heterogeneity in the rates of ICU admission is observed across different series (10%[61] to 31.6%[55]). It has been also proposed that the risk of death may be actually lower compared to the non-transplant population[51]. The outcome of post-transplant COVID-19 seems to depend mainly on the age of the recipient and the number of chronic comorbidities, rather than by the transplant status itself[59]. Some studies have suggested that post-transplant IS —in particular tacrolimus-containing regimens— may play a protective role by abrogating the deleterious effect of the cytokine release syndrome occurring during the course of SARS-CoV-2 infection or through a direct antiviral activity[83]. To date, there is scarce evidence to guide the use of antiviral or immunomodulatory therapies for COVID-19 after LT, including the potential effectiveness and safety of remdesivir or anti-IL-6 agents[82]. Both clinical experience and guidelines recommend the dose reduction of IS or withdrawal of MMF and other anti-proliferative agents[51,87]. Although specific studies are still scarce, messenger RNA vaccines seem to be safe in LT recipients in terms of serious adverse events or risk of alloimmunity, although the magnitude of SARS-CoV-2-specific immunoglobulin G antibody response is severely decreased as compared to non-immunocompromised individuals[97].

**REFERENCES**

1 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

2 **Zhu N**, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**: 727-733 [PMID: 31978945 DOI: 10.1056/NEJMoa2001017]

3 **World Health Organization.** WHO Director-General's opening remarks at the media briefing on COVID-19, 11 March 2020. [cited 17 February 2021]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

4 **World Health Organization.** WHO Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. [cited 10 June 21021]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>

5 COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. [cited 10 June 21021]. Available from: https://coronavirus.jhu.edu/map.html

6 **Fishman JA**. Infection in Organ Transplantation. *Am J Transplant* 2017; **17**: 856-879 [PMID: 28117944 DOI: 10.1111/ajt.14208]

7 **Chan JW**, Ng CK, Chan YH, Mok TY, Lee S, Chu SY, Law WL, Lee MP, Li PC. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). *Thorax* 2003; **58**: 686-689 [PMID: 12885985 DOI: 10.1136/thorax.58.8.686]

8 **Park JE**, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. *BMC Public Health* 2018; **18**: 574 [PMID: 29716568 DOI: 10.1186/s12889-018-5484-8]

9 **Zhang T**, Huang WS, Guan W, Hong Z, Gao J, Gao G, Wu G, Qin YY. Risk factors and predictors associated with the severity of COVID-19 in China: a systematic review, meta-analysis, and meta-regression. *J Thorac Dis* 2020; **12**: 7429-7441 [PMID: 33447431 DOI: 10.21037/jtd-20-1743]

10 **Raja MA**, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, Fernandez A, Guerra G, Camargo JF, Simkins J, Morris MI, Abbo LA, Natori Y. COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. *Transplant Rev (Orlando)* 2021; **35**: 100588 [PMID: 33246166 DOI: 10.1016/j.trre.2020.100588]

11 **Liu B**, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. *Am J Transplant* 2020; **20**: 1891-1895 [PMID: 32243673 DOI: 10.1111/ajt.15901]

12 **Huang JF**, Zheng KI, George J, Gao HN, Wei RN, Yan HD, Zheng MH. Fatal outcome in a liver transplant recipient with COVID-19. *Am J Transplant* 2020; **20**: 1907-1910 [PMID: 32277591 DOI: 10.1111/ajt.15909]

13 **Bhoori S**, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. *Lancet Gastroenterol Hepatol* 2020; **5**: 532-533 [PMID: 32278366 DOI: 10.1016/S2468-1253(20)30116-3]

14 **Fernández-Ruiz M**, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folgueira MD, Lalueza A, Lumbreras C, Aguado JM. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transplant* 2020; **20**: 1849-1858 [PMID: 32301155 DOI: 10.1111/ajt.15929]

15 **Kates OS**, Fisher CE, Stankiewicz-Karita HC, Shepherd AK, Church EC, Kapnadak SG, Lease ED, Riedo FX, Rakita RM, Limaye AP. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. *Am J Transplant* 2020; **20**: 1885-1890 [PMID: 32330356 DOI: 10.1111/ajt.15944]

16 **Pereira MR**, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, Arcasoy S, Aversa MM, Benvenuto LJ, Dadhania DM, Kapur S, Dove LM, Brown RS Jr, Rosenblatt RE, Samstein B, Uriel N, Farr MA, Satlin M, Small CB, Walsh TJ, Kodiyanplakkal RP, Miko BA, Aaron JG, Tsapepas DS, Emond JC, Verna EC. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. *Am J Transplant* 2020; **20**: 1800-1808 [PMID: 32330343 DOI: 10.1111/ajt.15941]

17 **Eslami P**, Moradi M, Dooghaie Moghadam A, Pirsalehi A, Abdul Lateef S, Hadaegh A, Rezai B, Sadeghi A, Asadzadeh Aghdaei H, Zali MR. Lethal outcome of Covid-19 pneumonia in a new liver recipient with neurological manifestation. *Gastroenterol Hepatol Bed Bench* 2020; **13**: 405-409 [PMID: 33244386]

18 **Qin J**, Wang H, Qin X, Zhang P, Zhu L, Cai J, Yuan Y, Li H. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. *Hepatology* 2020; **72**: 1491-1493 [PMID: 32220017 DOI: 10.1002/hep.31257]

19 **Jothimani D**, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. *J Hepatol* 2020; **73**: 1231-1240 [PMID: 32553666 DOI: 10.1016/j.jhep.2020.06.006]

20 **Zhong P**, Xu J, Yang D, Shen Y, Wang L, Feng Y, Du C, Song Y, Wu C, Hu X, Sun Y. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. *Signal Transduct Target Ther* 2020; **5**: 256 [PMID: 33139693 DOI: 10.1038/s41392-020-00373-7]

21 **Napodano C**, Pocino K, Stefanile A, Marino M, Miele L, Gulli F, Basile V, Pandolfi F, Gasbarrini A, Rapaccini GL, Basile U. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. *Scand J Immunol* 2021; **93**: e12977 [PMID: 32931622 DOI: 10.1111/sji.12977]

22 **McConnell MJ**, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee AI, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. *J Hepatol* 2021; **75**: 647-658 [PMID: 33991637 DOI: 10.1016/j.jhep.2021.04.050]

23 **Fiel MI**, El Jamal SM, Paniz-Mondolfi A, Gordon RE, Reidy J, Bandovic J, Advani R, Kilaru S, Pourmand K, Ward S, Thung SN, Schiano T. Findings of Hepatic Severe Acute Respiratory Syndrome Coronavirus-2 Infection. *Cell Mol Gastroenterol Hepatol* 2021; **11**: 763-770 [PMID: 32992052 DOI: 10.1016/j.jcmgh.2020.09.015]

24 **Cai Q**, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *J Hepatol* 2020; **73**: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]

25 **Ding ZY**, Li GX, Chen L, Shu C, Song J, Wang W, Wang YW, Chen Q, Jin GN, Liu TT, Liang JN, Zhu P, Zhu W, Li Y, Zhang BH, Feng H, Zhang WG, Yin ZY, Yu WK, Yang Y, Zhang HQ, Tang ZP, Wang H, Hu JB, Liu JH, Yin P, Chen XP, Zhang B; Tongji Multidisciplinary Team for Treating COVID-19 (TTTC). Association of liver abnormalities with in-hospital mortality in patients with COVID-19. *J Hepatol* 2021; **74**: 1295-1302 [PMID: 33347952 DOI: 10.1016/j.jhep.2020.12.012]

26 **Meszaros M**, Meunier L, Morquin D, Klouche K, Fesler P, Malezieux E, Makinson A, Le Moing V, Reynes J, Pageaux GP. Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: Should we worry? *Liver Int* 2020; **40**: 1860-1864 [PMID: 32495496 DOI: 10.1111/liv.14557]

27 **Phipps MM**, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verna EC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. *Hepatology* 2020; **72**: 807-817 [PMID: 32473607 DOI: 10.1002/hep.31404]

28 **Sharma P**, Kumar A, Anikhindi S, Bansal N, Singla V, Shivam K, Arora A. Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know? *J Clin Exp Hepatol* 2021; **11**: 484-493 [PMID: 33398223 DOI: 10.1016/j.jceh.2020.12.006]

29 **Rela M**, Patil V, Narasimhan G, Jothimani D. COVID-19 in decompensated cirrhosis. *Hepatol Int* 2020; **14**: 1125-1127 [PMID: 32990918 DOI: 10.1007/s12072-020-10092-4]

30 **Kumar P**, Sharma M, Sulthana SF, Kulkarni A, Rao PN, Reddy DN. Severe Acute Respiratory Syndrome Coronavirus 2-related Acute-on-chronic Liver Failure. *J Clin Exp Hepatol* 2021; **11**: 404-406 [PMID: 33398222 DOI: 10.1016/j.jceh.2020.12.007]

31 **Zhou YJ**, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Metabolic-associated fatty liver disease is associated with severity of COVID-19. *Liver Int* 2020; **40**: 2160-2163 [PMID: 32573883 DOI: 10.1111/liv.14575]

32 **Xu Z**, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; **8**: 420-422 [PMID: 32085846 DOI: 10.1016/S2213-2600(20)30076-X]

33 **Tian S**, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao SY. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. *Mod Pathol* 2020; **33**: 1007-1014 [PMID: 32291399 DOI: 10.1038/s41379-020-0536-x]

34 **Lagana SM**, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, Del Portillo A, De Michele S, de Gonzalez AK, Saqi A, Khairallah P, Chong AM, Park H, Uhlemann AC, Lefkowitch JH, Verna EC. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. *Mod Pathol* 2020; **33**: 2147-2155 [PMID: 32792598 DOI: 10.1038/s41379-020-00649-x]

35 **Amaddeo G**, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L, Ganne-Carrié N, Séror O, Larrey E, Lim C, Scatton O, El Mouhadi S, Ozenne V, Paye F, Balladur P, Dohan A, Massault PP, Pol S, Dioguardi Burgio M, Vilgrain V, Sepulveda A, Cauchy F, Luciani A, Sommacale D, Leroy V, Roudot-Thoraval F, Bouattour M, Nault JC; Paris Liver Cancer Group. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. *JHEP Rep* 2021; **3**: 100199 [PMID: 33163949 DOI: 10.1016/j.jhepr.2020.100199]

36 **De Simone P**, Melandro F, Balzano E, Tincani G, Catalano G, Ghinolfi D, Ducci J, Carrai P, Petruccelli S, Biancofiore G. Coronavirus Disease 2019 Infection Requires Strengthening of the Chronic Care Model: The Impact on Liver Transplant Practice at a High-Volume Center in Italy. *Liver Transpl* 2020; **26**: 1351-1353 [PMID: 32542881 DOI: 10.1002/lt.25821]

37 **Melandro F**, Ghinolfi D, Balzano E, Tincani G, Catalano G, Biancofiore G, Peris A, De Simone P. Light at the end of the tunnel: COVID-19 lockdown has not halted liver transplantation at a high volume center in Italy. *Transpl Int* 2020; **33**: 1845-1847 [PMID: 33034081 DOI: 10.1111/tri.13764]

38 **Gruttadauria S**; Italian Board of Experts in Liver Transplantation (I-BELT) Study Group, The Italian Society of Organ Transplantation (SITO). Preliminary Analysis of the Impact of the Coronavirus Disease 2019 Outbreak on Italian Liver Transplant Programs. *Liver Transpl* 2020; **26**: 941-944 [PMID: 32378325 DOI: 10.1002/lt.25790]

39 **Maggi U**, De Carlis L, Yiu D, Colledan M, Regalia E, Rossi G, Angrisani M, Consonni D, Fornoni G, Piccolo G, DeFeo TM. The impact of the COVID-19 outbreak on liver transplantation programs in Northern Italy. *Am J Transplant* 2020; **20**: 1840-1848 [PMID: 32330351 DOI: 10.1111/ajt.15948]

40 **Domínguez-Gil B**, Coll E, Fernández-Ruiz M, Corral E, Del Río F, Zaragoza R, Rubio JJ, Hernández D. COVID-19 in Spain: Transplantation in the midst of the pandemic. *Am J Transplant* 2020; **20**: 2593-2598 [PMID: 32359194 DOI: 10.1111/ajt.15983]

41 **Turco C**, Lim C, Soubrane O, Malaquin G, Kerbaul F, Bastien O, Conti F, Scatton O. Impact of the first Covid-19 outbreak on liver transplantation activity in France: A snapshot. *Clin Res Hepatol Gastroenterol* 2021; **45**: 101560 [PMID: 33176991 DOI: 10.1016/j.clinre.2020.10.005]

42 **Goff RR**, Wilk AR, Toll AE, McBride MA, Klassen DK. Navigating the COVID-19 pandemic: Initial impacts and responses of the Organ Procurement and Transplantation Network in the United States. *Am J Transplant* 2021; **21**: 2100-2112 [PMID: 33244847 DOI: 10.1111/ajt.16411]

43 **Friedman AL**, Delli Carpini KW, Ezzell C, Irving H. There are no best practices in a pandemic: Organ donation within the COVID-19 epicenter. *Am J Transplant* 2020; **20**: 3089-3093 [PMID: 32568471 DOI: 10.1111/ajt.16157]

44 **Reddy MS**, Hakeem AR, Klair T, Marcon F, Mathur A, Samstein B, Mohanka R, Mathur SK, Prachalias A, Menon KV, Muiesan P, Rela M, Emond JC. Trinational Study Exploring the Early Impact of the COVID-19 Pandemic on Organ Donation and Liver Transplantation at National and Unit Levels. *Transplantation* 2020; **104**: 2234-2243 [PMID: 32804803 DOI: 10.1097/TP.0000000000003416]

45 **Lee JM**. Effect of COVID-19 on liver transplantation in Korea. *Transpl Infect Dis* 2020; **22**: e13384 [PMID: 32574408 DOI: 10.1111/tid.13384]

46 **Montalbano M**, Levi Sandri GB, Visco Comandini U, Lionetti R, Vincenzi L, Berardi G, Guglielmo N, Pellicelli A, Ettorre GM, D'Offizi G. The impact of the coronavirus disease 2019 pandemic on a central Italy transplant center. *Medicine (Baltimore)* 2020; **99**: e22174 [PMID: 33031261 DOI: 10.1097/MD.0000000000022174]

47 **Siniscalchi A**, Vitale G, Morelli MC, Ravaioli M, Laici C, Bianchini A, Del Gaudio M, Conti F, Vizioli L, Cescon M. Liver transplantation in Italy in the era of COVID 19: reorganizing critical care of recipients. *Intern Emerg Med* 2020; **15**: 1507-1515 [PMID: 32979193 DOI: 10.1007/s11739-020-02511-z]

48 **Agopian V**, Verna E, Goldberg D. Changes in Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center-Level Variability. *Liver Transpl* 2020; **26**: 1052-1055 [PMID: 32369251 DOI: 10.1002/lt.25789]

49 **Strauss AT**, Boyarsky BJ, Garonzik-Wang JM, Werbel W, Durand CM, Avery RK, Jackson KR, Kernodle AB, Baker T, Snyder J, Segev DL, Massie AB. Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. *Am J Transplant* 2021; **21**: 1838-1847 [PMID: 33107180 DOI: 10.1111/ajt.16373]

50 **Putzer G**, Martini J, Gasteiger L, Mathis S, Breitkopf R, Hell T, van Enckevort A, Oberhuber R, Öfner D, Schneeberger S. Liver Transplantation Activity in the Eurotransplant Area Is Recovering Slowly During the COVID-19 Crisis. *Transplant Direct* 2020; **6**: e611 [PMID: 33134487 DOI: 10.1097/TXD.0000000000001064]

51 **Polak WG**, Fondevila C, Karam V, Adam R, Baumann U, Germani G, Nadalin S, Taimr P, Toso C, Troisi RI, Zieniewicz K, Belli LS, Duvoux C. Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. *Transpl Int* 2020; **33**: 1244-1252 [PMID: 32609908 DOI: 10.1111/tri.13680]

52 **Verma A**, Khorsandi SE, Dolcet A, Prachalias A, Suddle A, Heaton N, Jassem W. Low prevalence and disease severity of COVID-19 in post-liver transplant recipients-A single centre experience. *Liver Int* 2020; **40**: 1972-1976 [PMID: 32471013 DOI: 10.1111/liv.14552]

53 **Colmenero J**, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, Nuño J, Gastaca M, Bustamante-Schneider J, Cachero A, Lladó L, Caballero A, Fernández-Yunquera A, Loinaz C, Fernández I, Fondevila C, Navasa M, Iñarrairaegui M, Castells L, Pascual S, Ramírez P, Vinaixa C, González-Dieguez ML, González-Grande R, Hierro L, Nogueras F, Otero A, Álamo JM, Blanco-Fernández G, Fábrega E, García-Pajares F, Montero JL, Tomé S, De la Rosa G, Pons JA. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. *J Hepatol* 2021; **74**: 148-155 [PMID: 32750442 DOI: 10.1016/j.jhep.2020.07.040]

54 **Loinaz C**, Marcacuzco A, Fernández-Ruiz M, Caso O, Cambra F, San Juan R, Justo I, Calvo J, García-Sesma A, Manrique A, Pérez-Jacoiste Asín MA, Folgueira MD, Aguado JM, Lumbreras C. Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain. *Transpl Infect Dis* 2020; **22**: e13372 [PMID: 32562561 DOI: 10.1111/tid.13372]

55 **Ravanan R**, Callaghan CJ, Mumford L, Ushiro-Lumb I, Thorburn D, Casey J, Friend P, Parameshwar J, Currie I, Burnapp L, Baker R, Dudley J, Oniscu GC, Berman M, Asher J, Harvey D, Manara A, Manas D, Gardiner D, Forsythe JLR. SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study. *Am J Transplant* 2020; **20**: 3008-3018 [PMID: 32780493 DOI: 10.1111/ajt.16247]

56 **Trapani S**, Masiero L, Puoti F, Rota MC, Del Manso M, Lombardini L, Riccardo F, Amoroso A, Pezzotti P, Grossi PA, Brusaferro S, Cardillo M; Italian Network of Regional Transplant Coordinating Centers Collaborating group; Italian Surveillance System of Covid-19, Italian Society for Organ Transplantation (SITO), The Italian Board of Experts in Liver Transplantation (I-BELT) Study Group, Italian Association for the Study of the Liver (AISF), Italian Society of Nephrology (SIN), SIN-SITO Study Group. Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study. *Am J Transplant* 2021; **21**: 2509-2521 [PMID: 33278850 DOI: 10.1111/ajt.16428]

57 **Ali Malekhosseini S**, Nikoupour H, Gholami S, Shamsaeefar A, Arasteh P, Kazemi K, Dehghani M, Eghlimi H, Raeisi Shahraki H, Roozbeh J, Rezaianzadeh A, Nikeghbalian S. A Report of 85 Cases of COVID-19 and Abdominal Transplantation From a Single Center: What Are the Associated Factors With Death Among Organ Transplantation Patients. *Transplantation* 2021; **105**: 90-99 [PMID: 32976364 DOI: 10.1097/TP.0000000000003470]

58 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

59 **Kates OS**, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, Safa K, Kotton CN, Blumberg EA, Besharatian BD, Tanna SD, Ison MG, Malinis M, Azar MM, Rakita RM, Morillas JA, Majeed A, Sait AS, Spaggiari M, Hemmige V, Mehta SA, Neumann H, Badami A, Goldman JD, Lala A, Hemmersbach-Miller M, McCort ME, Bajrovic V, Ortiz-Bautista C, Friedman-Moraco R, Sehgal S, Lease ED, Fisher CE, Limaye AP; UW COVID-19 SOT Study Team. COVID-19 in solid organ transplant: A multi-center cohort study. *Clin Infect Dis* 2020 [PMID: 32766815 DOI: 10.1093/cid/ciaa1097]

60 **Belli LS**, Duvoux C, Karam V, Adam R, Cuervas-Mons V, Pasulo L, Loinaz C, Invernizzi F, Patrono D, Bhoori S, Ciccarelli O, Morelli MC, Castells L, Lopez-Lopez V, Conti S, Fondevila C, Polak W. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. *Lancet Gastroenterol Hepatol* 2020; **5**: 724-725 [PMID: 32505228 DOI: 10.1016/S2468-1253(20)30183-7]

61 **Webb GJ**, Marjot T, Cook JA, Aloman C, Armstrong MJ, Brenner EJ, Catana MA, Cargill T, Dhanasekaran R, García-Juárez I, Hagström H, Kennedy JM, Marshall A, Masson S, Mercer CJ, Perumalswami PV, Ruiz I, Thaker S, Ufere NN, Barnes E, Barritt AS 4th, Moon AM. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. *Lancet Gastroenterol Hepatol* 2020; **5**: 1008-1016 [PMID: 32866433 DOI: 10.1016/S2468-1253(20)30271-5]

62 **Caillard S**, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, Gatault P, Thaunat O, Legris T, Frimat L, Westeel PF, Goutaudier V, Jdidou M, Snanoudj R, Colosio C, Sicard A, Bertrand D, Mousson C, Bamoulid J, Masset C, Thierry A, Couzi L, Chemouny JM, Duveau A, Moal V, Blancho G, Grimbert P, Durrbach A, Moulin B, Anglicheau D, Ruch Y, Kaeuffer C, Benotmane I, Solis M, LeMeur Y, Hazzan M, Danion F; French SOT COVID Registry. Is COVID-19 infection more severe in kidney transplant recipients? *Am J Transplant* 2021; **21**: 1295-1303 [PMID: 33259686 DOI: 10.1111/ajt.16424]

63 **Becchetti C**, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, Dahlqvist G, Ciccarelli O, Morelli MC, Fraga M, Svegliati-Baroni G, van Vlierberghe H, Coenraad MJ, Romero MC, de Gottardi A, Toniutto P, Del Prete L, Abbati C, Samuel D, Pirenne J, Nevens F, Dufour JF; COVID-LT group. COVID-19 in an international European liver transplant recipient cohort. *Gut* 2020; **69**: 1832-1840 [PMID: 32571972 DOI: 10.1136/gutjnl-2020-321923]

64 **Richardson S**, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020; **323**: 2052-2059 [PMID: 32320003 DOI: 10.1001/jama.2020.6775]

65 **Prieto M**, Gastaca M, Ruiz P, Ventoso A, Palomares I, Rodríguez-Álvarez RJ, Salvador P, Bustamante J, Valdivieso A. A case of COVID-19 immediately after liver transplantation: Not only bad news. *Ann Hepatobiliary Pancreat Surg* 2020; **24**: 314-318 [PMID: 32843598 DOI: 10.14701/ahbps.2020.24.3.314]

66 **Rouphael C**, D'Amico G, Ricci K, Cywinski J, Miranda C, Koval C, Duggal A, Quintini C, Menon KVN, Miller C, Modaresi Esfeh J. Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose. *Am J Transplant* 2021; **21**: 1312-1316 [PMID: 33017864 DOI: 10.1111/ajt.16330]

67 **Sanghavi DK**, Lowman PE, Harnois DM, Keaveny AP, Nguyen JH, Canabal JM, Moreno Franco P. Changes in Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center-Level Variability. *Liver Transpl* 2020; **26**: 1672-1673 [PMID: 32858781 DOI: 10.1002/lt.25877]

68 **Raut V**, Sonavane A, Shah K, Raj C A, Thorat A, Sawant A, Chaksota H, Mandot A, Vasanth S, Nagral A, Mirza D. Successful liver transplantation immediately after recovery from COVID-19 in a highly endemic area. *Transpl Int* 2021; **34**: 376-377 [PMID: 33253449 DOI: 10.1111/tri.13790]

69 **Martini S**, Patrono D, Pittaluga F, Brunetto MR, Lupo F, Amoroso A, Cavallo R, Balagna R, Romagnoli R. Urgent liver transplantation soon after recovery from COVID-19 in a patient with decompensated liver cirrhosis. *Hepatol Commun* 2020 [PMID: 32838105 DOI: 10.1002/hep4.1580]

70 **Fraser J**, Mousley J, Testro A, Smibert OC, Koshy AN. Clinical Presentation, Treatment, and Mortality Rate in Liver Transplant Recipients With Coronavirus Disease 2019: A Systematic Review and Quantitative Analysis. *Transplant Proc* 2020; **52**: 2676-2683 [PMID: 32891405 DOI: 10.1016/j.transproceed.2020.07.012]

71 **Coll E**, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, Bada-Bosch T, Oppenheimer F, Moreso F, López-Oliva MO, Melilli E, Rodríguez-Ferrero ML, Bravo C, Burgos E, Facundo C, Lorenzo I, Yañez Í, Galeano C, Roca A, Cabello M, Gómez-Bueno M, García-Cosío M, Graus J, Lladó L, de Pablo A, Loinaz C, Aguado B, Hernández D, Domínguez-Gil B; Spanish Group for the Study of COVID-19 in Transplant Recipients. COVID-19 in transplant recipients: The Spanish experience. *Am J Transplant* 2021; **21**: 1825-1837 [PMID: 33098200 DOI: 10.1111/ajt.16369]

72 **Rezaee H**, Pourkarim F, Pourtaghi-Anvarian S, Entezari-Maleki T, Asvadi-Kermani T, Nouri-Vaskeh M. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. *Pharmacol Res Perspect* 2021; **9**: e00705 [PMID: 33421347 DOI: 10.1002/prp2.705]

73 **Cao B**, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* 2020; **382**: 1787-1799 [PMID: 32187464 DOI: 10.1056/NEJMoa2001282]

74 **Cavalcanti AB**, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramujas L, Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, Machado FR, Berwanger O; Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med* 2020; **383**: 2041-2052 [PMID: 32706953 DOI: 10.1056/NEJMoa2019014]

75 **WHO Solidarity Trial Consortium.**, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med* 2021; **384**: 497-511 [PMID: 33264556 DOI: 10.1056/NEJMoa2023184]

76 **Beigel JH**, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020; **383**: 1813-1826 [PMID: 32445440 DOI: 10.1056/NEJMoa2007764]

77 **Fajgenbaum DC**, June CH. Cytokine Storm. *N Engl J Med* 2020; **383**: 2255-2273 [PMID: 33264547 DOI: 10.1056/NEJMra2026131]

78 **van Paassen J**, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. *Crit Care* 2020; **24**: 696 [PMID: 33317589 DOI: 10.1186/s13054-020-03400-9]

79 **Fernández-Ruiz M**, López-Medrano F, Aguado JM. Tocilizumab for the treatment of COVID-19. *Expert Opin Biol Ther* 2021; **21**: 431-434 [PMID: 33504238 DOI: 10.1080/14712598.2021.1880563]

80 **Generali D**, Bosio G, Malberti F, Cuzzoli A, Testa S, Romanini L, Fioravanti A, Morandini A, Pianta L, Giannotti G, Viola EM, Giorgi-Pierfranceschi M, Foramitti M, Tira RA, Zangrandi I, Chiodelli G, Machiavelli A, Cappelletti MR, Giossi A, De Giuli V, Costanzi C, Campana C, Bernocchi O, Sirico M, Zoncada A, Molteni A, Venturini S, Giudici F, Scaltriti M, Pan A. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. *Int J Infect Dis* 2021; **104**: 433-440 [PMID: 33385581 DOI: 10.1016/j.ijid.2020.12.073]

81 **Kalil AC**, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med* 2021; **384**: 795-807 [PMID: 33306283 DOI: 10.1056/NEJMoa2031994]

82 **RECOVERY Collaborative Group**, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**: 693-704 [PMID: 32678530 DOI: 10.1056/NEJMoa2021436]

83 **Fernández-Ruiz M**, Aguado JM. Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. *Curr Transplant Rep* 2020: 1-11 [PMID: 33110739 DOI: 10.1007/s40472-020-00306-x]

84 **Belli LS**, Fondevila C, Cortesi PA, Conti S, Karam V, Adam R, Coilly A, Ericzon BG, Loinaz C, Cuervas-Mons V, Zambelli M, Llado L, Diaz-Fontenla F, Invernizzi F, Patrono D, Faitot F, Bhooori S, Pirenne J, Perricone G, Magini G, Castells L, Detry O, Cruchaga PM, Colmenero J, Berrevoet F, Rodriguez G, Ysebaert D, Radenne S, Metselaar H, Morelli C, De Carlis LG, Polak WG, Duvoux C; ELITA-ELTR COVID-19 Registry. Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. *Gastroenterology* 2021; **160**: 1151-1163.e3 [PMID: 33307029 DOI: 10.1053/j.gastro.2020.11.045]

85 **Pereira MR**, Aversa MM, Farr MA, Miko BA, Aaron JG, Mohan S, Cohen DJ, Husain SA, Ratner LE, Arcasoy S, Uriel N, Zheng EX, Fox AN, Tsapepas DS, Emond JC, Verna EC. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. *Am J Transplant* 2020; **20**: 3198-3205 [PMID: 32946668 DOI: 10.1111/ajt.16314]

86 **Romanelli A**, Mascolo S. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis. *Am J Transplant* 2020; **20**: 1947-1948 [PMID: 32243698 DOI: 10.1111/ajt.15905]

87 **Carbajo-Lozoya J**, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. *Virus Res* 2012; **165**: 112-117 [PMID: 22349148 DOI: 10.1016/j.virusres.2012.02.002]

88 **Polack FP**, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**: 2603-2615 [PMID: 33301246 DOI: 10.1056/NEJMoa2034577]

89 **Baden LR**, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021; **384**: 403-416 [PMID: 33378609 DOI: 10.1056/NEJMoa2035389]

90 **Boyarsky BJ**, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. *JAMA* 2021; **325**: 2204-2206 [PMID: 33950155 DOI: 10.1001/jama.2021.7489]

91 **Grupper A**, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, Katchman E, Halperin T, Turner D, Goykhman Y, Shibolet O, Levy S, Houri I, Baruch R, Katchman H. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. *Am J Transplant* 2021; **21**: 2719-2726 [PMID: 33866672 DOI: 10.1111/ajt.16615]

92 **Rozen-Zvi B**, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A, Tau N, Mashraki T, Nesher E, Rahamimov R. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. *Clin Microbiol Infect* 2021; **27**: 1173.e1-1173.e4 [PMID: 33957273 DOI: 10.1016/j.cmi.2021.04.028]

93 **Shostak Y**, Shafran N, Heching M, Rosengarten D, Shtraichman O, Shitenberg D, Amor SM, Yahav D, Ben Zvi H, Pertzov B, Kramer MR. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. *Lancet Respir Med* 2021; **9**: e52-e53 [PMID: 33964244 DOI: 10.1016/S2213-2600(21)00184-3]

94 **Miele M**, Busà R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F, Mularoni A, Panarello G, Vitulo P, Conaldi PG, Bulati M. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. *Am J Transplant* 2021; **21**: 2919-2921 [PMID: 34058052 DOI: 10.1111/ajt.16702]

95 **Cucchiari D**, Egri N, Bodro M, Herrera S, Del Risco-Zevallos J, Casals-Urquiza J, Cofan F, Moreno A, Rovira J, Banon-Maneus E, Ramirez-Bajo MJ, Ventura-Aguiar P, Pérez-Olmos A, Garcia-Pascual M, Pascal M, Vilella A, Trilla A, Ríos J, Palou E, Juan M, Bayés B, Diekmann F. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. *Am J Transplant* 2021; **21**: 2727-2739 [PMID: 34036720 DOI: 10.1111/ajt.16701]

96 **Rabinowich L**, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, Katchman E, Levi S, Houri I, Lubezky N, Shibolet O, Katchman H. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. *J Hepatol* 2021; **75**: 435-438 [PMID: 33892006 DOI: 10.1016/j.jhep.2021.04.020]

97 **American Association for the Study of Liver Diseases (AASLD).** Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement (updated November 9, 2020). [cited 18 February 2021]. Available from: <https://www.aasld.org/sites/default/files/2020-11/AASLD-COVID19-ExpertPanelConsensusStatement-November092020.pdfts>

98 **Russo FP**, Piano S, Bruno R, Burra P, Puoti M, Masarone M, Montagnese S, Ponziani FR, Petta S, Aghemo A; Italian Association for the Study of the Liver. Italian association for the study of the liver position statement on SARS-CoV2 vaccination. *Dig Liver Dis* 2021; **53**: 677-681 [PMID: 33941488 DOI: 10.1016/j.dld.2021.03.013]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that there are no any conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 21, 2021

**First decision:** June 4, 2021

**Article in press:** August 23, 2021

**Specialty type:** Infectious diseases

**Country/Territory of origin:** Spain

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Magro B, Romanzi A, Seki M **S-Editor:** Ma YJ **L-Editor:** Filipodia **P-Editor:** Li X



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**